Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Income from Non-Controlling Interests (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Income from Non-Controlling Interests for 3 consecutive years, with -$23000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Income from Non-Controlling Interests rose 62.9% year-over-year to -$23000.0, compared with a TTM value of $801000.0 through Sep 2024, up 181.4%, and an annual FY2023 reading of $437000.0, up 136.33% over the prior year.
  • Income from Non-Controlling Interests was -$23000.0 for Q3 2024 at Oramed Pharmaceuticals, down from -$8000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $834000.0 in Q4 2023 and bottomed at -$587000.0 in Q4 2022.
  • Average Income from Non-Controlling Interests over 3 years is -$108454.5, with a median of -$119000.0 recorded in 2023.
  • Peak annual rise in Income from Non-Controlling Interests hit 242.08% in 2023, while the deepest fall reached 23.67% in 2023.
  • Year by year, Income from Non-Controlling Interests stood at -$587000.0 in 2022, then surged by 242.08% to $834000.0 in 2023, then tumbled by 102.76% to -$23000.0 in 2024.
  • Business Quant data shows Income from Non-Controlling Interests for ORMP at -$23000.0 in Q3 2024, -$8000.0 in Q2 2024, and -$2000.0 in Q1 2024.